Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Decision on EU marketing authorisation expected for momelotinib by early 2024
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Subscribe To Our Newsletter & Stay Updated
